Lutetium Lu 177-DTPA-omburtamab

DB31015InvestigationalProtein Based Therapies

Lutetium Lu 177-DTPA-omburtamab is a radioimmunoconjugate made up of omburtamab conjugated with lutetium Lu 177 via the chelating agent of diethylenetriaminepentaacetic acid (DTPA).

Mechanism: Pharmacologically active on CD276 antigen
Curator reviewed
Also known as: 177Lu-DTPA-omburtamab · DTPA-omburtamab

Resolves to

Compound

UNIIXM7ZD3T6AE

Targets

Q5ZPR3CD276

What you can answer from here — as of July 02, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lutetium Lu 177-DTPA-omburtamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account